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Asbtract
Interstitial lung diseases (ILD) are known as a debilitating 
pulmonary complications that may be occured in almost 
all systemic connective tissue diseases (CTD), including 
mixed connective tissue disease (MCTD). ILD is usually 
found in more than half of MCTD patients after 2-4 
years after the diagnosis made. A-47-years-old female 
initially diagnosed as systemic lupus erythematosus 
(SLE) developed a severe progressive dyspnea. She 
has recently diagnosed as MCTD with ILD after 9 
months of initial symptoms. She was giving with 
Cyclophosphamide 500 mg IV pulse dose. However, 
after 1 months she developed severe pneumonia and 
pronounced demise due to intractable septic shock. 
The debilitating course of ILD is commonly seen in most 
systemic CTD. Therefore, it is important to perform initial 
screening and prevention. Systemic corticosteroid with 
or without immunosupressor agent(s) are indicated in 
ILD-MCTD. Patients with progressive diseases will have 
poor prognosis.
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Introduction
Interstitial lung disease (ILD) and pulmonary 
hypertension (PH) are known as the main cause 
of mortality and morbidity among patients with 
Collagen vascular disease (CVD).1,2 ILD is a 
heterogeneous group of non-neoplastic parenchymal 
lung disorders hallmarked by vary degrees of 
inflammation and fibrosis that share common 
radiologic, pathologic, and clinical manifestation.3 
ILD does not only affect the interstitium but also 
the airspaces, peripheral airways, and vessels 
respectively with their epithelial and endothelial 
linings. ILD, one of CTD manisfestation, seldomly 
occurs in MCTD.4 In CTD, there are two major 
presentations of ILD; first ILD can be the initial 
symptoms or become one of the symptoms of 
CTD,4 second ILD found as interstitial pneumonia 
in patients who do not meet the CTD criteria, 
but later defined as interstitial pneumonia with 
autoimmune features (IPAF).5
Here we present a case of a 47 years old woman 
with chronic cough, progressive dyspnea, and 
previous history of SLE and Scleroderma. She was 
later diagnosed as ILD  and CTD due to MCTD and 
underwent cyclophosphamide IV pulse therapy. 
Case Ilustration
A 47 years old female refered to our institution 
due to progressive dyspnea for 2 weeks prior to 
admission (PTA).
Nine months PTA she complained of intermittent 
fever. She had non reproductive cough and multiple 
swollen-tender joints. Yet denied any weakness, 
abdominal pain, facial erythema, morning stiffness, 
hair loss, and dysuria. She had given medicines to 
relive the symptoms, but no relieve were noted yet.
Six months PTA, persistent fever, joint pain 
and non-productive cough were noted. She 
developed dyspnea on activity, facial erythema 
with sun exposure,  hair loss, multiple oral ulcers, 
and weakness notably over her both legs. She also 
complained morning stiffness persist more than 30 
minutes over both arms, and multiple assymetry 
swollen-tender joints. There were features of 
scleroderma and Reynauds phenomenon. Further, 
there were positive anti neutrophilic antibody 
(ANA), hence diagnosed as systemic lupus 
erymathosus (SLE) and she got methyl-prednisone 
(MP) daily 3x4 mg peroral (PO).
Four months PTA, the swollen joints were 
improved, persistent fever back to intermittent 
fever. But the other symptoms were persisted. She 
regularly consulted to her physician and got MP 3x4 
mg/PO daily. Further assessment showed moderate 
positivity of ANA anti-SCL 70, and anti Sm-RNP 
which brought the diagnosis to scleroderma. So, 
additional methotrexate (MTX) 1x5 mg/PO and 
folic acid 1x5 mg/PO weekly were given. 
Two weeks PTA, she had another episode 
of high grade fever, cough and dyspnea. She 
readmitted to hospital due to severe pneumonia for 
1 weeks. From the hospital, she was referred to our 
institution.
In her previous medical history, she has been 
treated for lymphadenitis tuberculosis 2 times with 
undocumented treatment. She is non-smoker and 
non-alcoholic drinker, denies any promiscuities and 
narcotics. She had a history of previous miscarriage 
below 18 weeks of gestation on her third pregnancy.
When assesment made, she was alert and had 
mild respiratory distress. Blood pressure : 90/60 
mmHg, Heart rate: 105/min, respiratory rate: 24 
cycle/min, temperature: 38°C. Her face shown a 
normal facial expression with thickening. There 
were some area show non scarring hair loss, pale 
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palpebral conjunctiva, multiple palatal ulcers and jugular 
venous pressure noted 5+0 cmH2O. Chest and lung assesment 
showed normal vesicular breath sound with bilateral basal 
crackles and negative wheezes. There were tenderness 
over both shoulders, elbows, right knee, and right foot; 
skin thickening on both arms and feet; periungual ulcers; 
Reynaud’s phenomenon; and vascular telangiectasia over the 
plantar of both feet.
Laboratory test were performed, such as complete blood 
count, liver function test, renal function test, coagulation 
state, electrolytes, metabolic activity, inflammation state, and 
screening TB, hepatitis B, and hepatitis C infection. Besides, 
we also performed analysis for ANA state. Screening for 
HIV, tuberculosis, hepatitis B and C showed unremarkable 
results. For the other laboratory results is shown in Table 
1. Her electrocardiography (ECG) findings showed sinus 
tachycardia.  No other abnormalities were found. Chest X-ray 
finding showed bilateral lung infiltrate with normal heart size 
as shown in Figure 1.
Table 1. Laboratory Examination
Test Result Reference
Hemoglobin 10.4 11.0-13.0 mg/dL
Hematocrite 30.7 40-50%
Leucocyte 4.550 5.000-10.000/µL
Trombocyte 151.000 150.000-400.000/µL
MCV/MCH/MCHC 83.5/28.2/33.8
Diff count 0/0/76/21/3
D-dimer 500 0.0-0.3 mg/dL
Fibrinogen 302.2 150-400 mg/dL
APTT 36.4 (35.1) 31-47.0 (s) 
PT 9.2 (10.4) 9.8-11.2 (s)
Albumin 3.10 3.4-4.8 g/dL
Globulin 3.79 1.8-3.9 g/dL
Total protein 6.89 6.4-8.7 g/dL
SGPT (ALT) 2 0-49 u/L
SGOT (AST) 126 0-32 u/L
Uric acid 7.4 0-6.9 mg/dL
Creatinine 0.559 0.8-1.3 mg/dL
Ureum 28.3 0-49 mg/dL
Natrium 142 132-147 mEq/L
Kalium 3.4 3.3-5.4 mEq/L
Clorida 112 94-111 mEq/L
LDH 569 <2155 U/L
GDS 92 0-200 mg/dL
HBsAg Non reaktif Non reaktif
CRP 40 <5 mg/L
Anti HCV Non reaktif Non reaktif
Microalbuminuria 67.5 mg/24 hours
TB Screening
IGRA
Gene Xpert
AFB smears 3 times
Unremarkable
Negative
Negative
BGA 7.5/26.1/100/24.1/-2.5/98.7
Autoimune Analysis
ANA Positive 1/1000 (homogen)
B2GP-IgM
B2GP-IgG
21.2 U
4.3 U
<20 U
<20 U
Lupus anticoagulant Weak positive negative
Anti-ds DNA 9.4 <100 IU/mL
CK 58 U/L <192 U/L
ACA IgM
ACA IgG
26.4 low to medium 
positive
25.1 low to medium 
positive
C3
C4
6
16
90-180 mg/dL
10-40 mg/dL
Rheumatoid Factor 12 <14 U/ml
Figure 1. Chest X-ray
Note: Bilateral infiltrate in both lungs’ base.
Patient was initially diagnosed as Health Care Associated 
Pneumonia (HCAP), MCTD with possible ILD, and anemia. 
She treated with cefepime 2x1 gr/IV, N-acetylcysteine 
1x600 mg/PO, and nebulization with salbutamol 3x2.5 mg. 
MTX were given subsequently and increased to 1x10 mg/
PO/week. Other medications, included: cilostazol 2x50 mg/
PO, omeprazole 1x20mg/PO, folic acid 5 mg/PO/weeks, 
nifedipine 1x10 mg/PO and MP 3x4 mg/PO were continued. 
Chest CT-scan shown a typical finding for ILD with possible 
undifferentiated interstitial pneumonitis (UIP) or nonspecific 
interstitial pneumonitis (NSIP) (Figure 2). Spirometry showed 
a restrictive pattern with low FEV1: 1.26 L or 40.6% predicted. 
Echocardiography showed: a normal ejection fraction (EF) 
62% with no signs of pulmonary hypertension. Skin biopsy 
resulted consistent with scleroderma. Bone surveys showed: 
signs of multiple erosion and osteopenia. Electromyograph 
revealed carpal tunnel syndrome over left arm and myotonic 
lesion over the lower extremities. Then patient treated with 
fluticasone - salmeterol 500mcg/50mcg two times daily 
attenuation, oral cavit D3 thrice daily, oral zolendronic 35mg/
weekly, she was planned to undergo cyclophosphamide pulse 
dose 500 mg/IV. First dose of intravenous cyclophosphamide 
500m mg was started as the clinical condition improved, and 
continued every two weeks until 6 doses given. 
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Figure 2. Patient Chest CT-scan
Note: Chest CT-scan showed ground glass opacity and traction 
bronchiectasis in subpleura and both lung base (arrow sign); 
multiple lymphadenopathies of paratrakeal and sub carinal.
Unfortunately, after 1 month of treatment, she readmitted 
due to the progression of dyspnea. The clinical findings 
notably showed the progression of ILD, but the clinicians 
denied to give further dose of cyclophosphamide. She was 
hospitalized and developed sepsis due to hospital acquired 
pneumonia (HAP) in the fourth day of hospitalization. She 
got treatment contained intravenous meropenem 3x1 gr daily 
and intravenous levofloxacin 500 mg daily. However on the 
8th day,she pronounced death due to irreversible septic shock.
MCTD and pulmonary involvement
MCTD was first described by Sharp et al (1971- 72) as 
a distinct syndrome with similar features of systemic 
lupus erythematosus (SLE), systemic sclerosis (SSC), 
dermatomyositis/polymyositis and rheumatoid arthritis 
(RA). The disease was associated with autoantibodies to 
ribonuclease – sensitive component of extractable nuclear 
antigen (U1 RNP).7 It is a rare disease and affected only 
2.7/1.000.000 patients in Japan population. Various studies 
show the correlation between the disease and the existence of 
HLA-DR4 and HLA-DR2. The clinical symptoms of MCTD 
usually takes several years before the diagnosis of MCTD 
established. Diagnosis of MCTD can be made using criteria 
from Alarcon-Segovia and Kahn which have sensitivity 
62.5% and specificity 86.2%.8 Our patients showed moderate 
positive U1 RNP, Reynaud’s phenomenon, acrosclerosis, 
history of synovitis, and possible myositis hence satisfy the 
diagnosis of MCTD.
The presence of pulmonary involvement occurs in 
75% patients.8 Common pulmonary problems could be 
found, such as: pleural effusion (50%),10 pleuritic pain, 
pulmonary hypertension, ILD, thromboembolic disease, 
alveolar hemorrhage, diaphragmatic dysfunction, aspiration 
pneumonitis/pneumonia, obstructive airway disease, 
pulmonary infections, pulmonary vasculitis.7 Vegh, et al 
reported from 179 patients with MCTD, 96 patients (53.6%) 
had ILD, with onset approximately 2-4 years prior to the 
presence of the symptoms.11which confirmed common 
interstitial pneumonitis. The patients were followed-up, and 
the data of computed tomography and respiratory function 
tests were detected 6 months, and then 4 years after the acute 
lung disease complicated by mixed connective tissue disease. 
RESULTS: Out of the 179 mixed connective tissue disease 
patients 96 (53.6% Meanwhille Gunnarsson, et al reported 
that abnormal pulmonary function tests (PFTs) restrictive 
pattern were seen in up to 90% of patients with MCTD.13 This 
finding is compatible with our patient. 
Pathophysiology ILD in MCTD
The role of autoimmunity in ILD associated with CTD is well 
established. The higher concentration of proinflammatory and 
profibrotic mediators have been implicated in the pathogenesis 
of ILD and IPF, and might also have important roles in 
SSc-associated ILD. Those mediators include chemokines, 
cytokines, growth factors, lipids, and prostanoids. The 
pivotal mediator of fibrosis is the multifunctional cytokines, 
transforming growth factor beta (TGFβ). Substantial evidences 
implicate that TGFβ – along with platelet-derived growth 
factor, endothelin-1 (ET-1), and other cytokines – plays role 
in the pathogenesis of SSc.3 (Figure 3).
Figure 3. Pathogenesis ILD and pulmonary fibrosis in MCTD.3 
CTGF: connective tissue growth factor; IGF-1: insulin-like growth 
factor-1; LPA: lysophosphatidic acid; TGF-β: transforming growth 
factor beta 
 Pathologic findings of pulmonary involvement of MCTD 
are classified into interstitial fibrosis and vascular changes.15 
Interstitial fibrosis typicaly shows appearance as UIP. It 
causes distortion of the alveolar architecture. On the other 
hand, vascular changes are typicaly consisted of bland intimal 
proliferation of the lung arterioles,10 plexiogenic angiopathy, 
and chronic pulmonary emboli, which subsequently cause 
pulmonary hypertension.8 
Approach to patient with ILD in CTD
As discussed above pulmonary manifestation may vary in 
MCTD. A comprehensive history assesment may provide 
valuable informations lead to certain diseases, include CTD-
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ILD. Differential diagnosis can be narrowed when the history 
and clinical findings combined with appropriate measurements 
of lung function and specific blood tests such as autoimmune 
serologies consistent to CTD. Moreover, if suspected extra-
pulmonary tissue sampling (e.g. lymph node or skin biopsy) 
and thoracic imaging can be performed. Clinical approach 
for diagnosing ILD-CTD is represented in Figure 4. Assesing 
spesific cause of ILD may needed invasive diagnostics 
(bronchoscopy, biopsy and bronchoalveolar lavage).
Figure 4. Approach to the diagnosis in ILD-CTD16
 
BAL: bronchoalveolar lavage fluid, HRCT:- High resolution 
computed tomography; ILd: Interstitial lung disease; VATS: video 
assisted thoracoscopic surgery. 
When ILD is suspected, chest X-ray is recommended to 
be performed in two projections posterior-anterior and lateral 
view. Chest X-ray can show an interstitial pattern in 19% 
of population. The other findings consist of irregular linear 
hyperattenuating areas with a reticular pattern and involving 
mainly the lung bases.15 In the late stage, honeycomb 
apperance may be identified. 
High Resolution-CT (HRCT) of the chest is the most 
sensitive test in establishing ILD diagnosis.8 In previous 
study, ILD was detected in 48% of MCTD patients using 
HRCT.17often serious, manifestation of mixed connective 
tissue disease (MCTD However, HRCT result should be 
supported by clinical symptoms and histopatological results. 
Because, in some cases it may mimic the other diseases, such 
as: NSIP and UIP. Study by Kosuka, et al found that ground-
glass attenuation almost identified in all ILD patients. Other 
frequent findings seen by HRCT were intralobular reticular 
opacity, traction bronchiectasis, honeycombing, subpleural 
small nodules, and non-septal linear opacity predominant 
in the lower and peripheral lung fields.15 Radiologic 
abnormalities include areas of parenchymal consolidation that 
may be related to BOOP (bronchiolitis obliterans organizing 
pneumonia). 18 
Bronchoscopy and/or surgical lung biopsy may be 
required to make a more convince diagnose of specific ILD.6 
The right middle lobe or lingula of the left upper lobe are 
likely to be the best regions to perform lavage when diffuse 
disease is present. Areas with ground-glass opacification or 
profuse nodular change are more likely to provide useful 
diagnostic information.16 Endobronchial biopsy provide 
useful information if endobronchial abnormalities are 
present (e.g. superficial nodules, mucosal ulceration). Trans 
bronchial lung biopsy is best performed far from the area of 
advanced fibrosis. A surgical lung biopsy (SLB) obtained via 
videoassisted thoracic surgery (VATS) or open biopsy is likely 
to provide an excellent specimen.16  
The main histopatologic changes of pulmonary 
involvement in MCTD is classified into interstitial fibrosis 
and vascular changes. Interstitial fibrosis has the appearance 
of usual or NSIP. Typical vascular changes consist of bland 
intimal proliferation of the lung arterioles, plexogenic 
angiopathy and chronic pulmonary emboli.18 Histopatologic 
examination could be used to confirm the presence of ILD 
however the results may vary. Most patient ILD due to MCTD 
shows histopatologic pattern  of NSIP followed by UIP.3
Treatment ILD-MCTD
The general strategies recommended for managing idiopathic 
pulmonary fibrosis (IPF) are often applied in CTD-ILD. 
These include the use of supplemental oxygen in patients 
with resting hypoxemia and treatment of asymptomatic 
gastroesophageal reflux disease (GERD).4 There are no 
specific guidelines exist for managing acute exacerbations of 
ILD in CTD. Interventions commonly give, included: Broad 
spectrum antimicrobials, coverage for pneumocystis jirovecii 
and fungal is considered based on risk factors. Risk factor 
assessed, such as preexisting immunosuppression, removal of 
the offending agents if drug toxicity suspected. High doses of 
pulse methylprednisolone (1g IV daily for three days) and IV 
or oral cyclophosphamide is considered.4 
 There is a few published literatures regarding the 
correlation of histology findings in ILD associated with MCTD 
and the use of immunosupresive therapy. Administration of 
immunosupressive therapy, such as corticosteroid, DMARD, 
or others immunosuppressive drugs showed no significant 
evidence for a better outcome.10 However, we found one 
study which showed 47% of patients with MCTD-ILD 
respond better to 2 mg/kg/day corticosteroids.17often serious, 
manifestation of mixed connective tissue disease (MCTD On 
the first admission our patient got broad spectrum antibiotic, 
cefepime 2x1 gr/IV, after that she treated with intravenous 
cyclophosphamide pulse therapy.
Other consideration in treating ILD is assessing any other 
comorbid conditions.4 For example pulmonary hypertension 
(PH). It is diagnosed if mean pulmonary artery pressure found 
≥25 mmHg. Therefore it can only be diagnosed by right heart 
catheterization. Therapy for PAH is quite specific, it is included 
anticoagulation, oxygen, diuretics, and pulmonary vascular 
vasodilators, phosphodiesterase inhibitor, imunosupressant.10 
Conclusion
Pulmonary manifestations of MCTD patients may vary 
from mild to severe respiratory symptoms. The hallmark of 
pulmonary manifestation in MCTD is vasculopathy and PH 
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which manifestated as progressive dyspnea, chronic cough, 
and even hemoptysis. A history of progressive dyspnea and 
typical HRCT findings is required in order to establish the 
diagnosis of ILD-MCTD. There was no specific recommended 
guidelines for the treatment of ILD-MCTD. Several case 
reports shown the improved of patient’s survival when using 
pulse dose corticosteroid and immunosuppressant. Some 
patients only respond to high dose corticosteroid. 
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